Francisco Esteva: HER2-targeted therapies are being explored for various other solid tumors
Francisco Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn about a recent paper by Jeesun Yoon and Do-Youn Oh published in Nature Reviews Clinical Oncology.
“HER2-targeted therapies beyond breast cancer — an update”
“HER2-targeted therapies, initially developed for breast and gastric cancers, are now being explored for various other solid tumors.
Advancements include the use of trastuzumab deruxtecan as a new standard for treatment-refractory HER2-positive cancers, the introduction of pembrolizumab with trastuzumab and chemotherapy as a first-line option for advanced HER2-positive gastric cancer patients.
Innovative therapies and clinical trials are underway to target HER2 in diverse tumor types.”
Source: Francisco Esteva/LinkedIn
More posts featuring Francisco Esteva on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023